Richard A. Miller

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

Lee Honigberg, Ashley M. Smith, Mint Sirisawad et al. · Proceedings of the National Academy of Sciences · 2010 · 1.5K citations · Full text

Life Sciences, Immunology, Pharmacology +17

Induction of Immune Responses in Patients with B-Cell Lymphoma against the Surface-Immunoglobulin Idiotype Expressed by Their Tumors

Larry W. Kwak, Michael J. Campbell, Debra K. Czerwinski et al. · New England Journal of Medicine · 1992 · 545 citations

Life Sciences, Immunology, Oncology +17

Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer

Lawrence Fong, Andrew Hotson, John D. Powderly et al. · Cancer Discovery · 2019 · 339 citations · Full text

Medicine, Immunology, Oncology +17

Evaluation of Resveratrol, Green Tea Extract, Curcumin, Oxaloacetic Acid, and Medium-Chain Triglyceride Oil on Life Span of Genetically Heterogeneous Mice

Randy Strong, Richard A. Miller, Clinton M. Astle et al. · The Journals of Gerontology Series A · 2012 · 231 citations · Full text

Education, Nutritional Sciences, Pharmacology +13

A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti–PD-(L)1 and Anti–CTLA-4 in Preclinical Models

Stephen B. Willingham, Po Y. Ho, Andrew Hotson et al. · Cancer Immunology Research · 2018 · 217 citations

Medicine, Immunology, Pharmacology +17